I型干扰素通过上调IRF-1介导SLE单核细胞炎性小体活性增强
该研究探讨I型干扰素是否通过IRF-1调控SLE患者单核细胞的炎性小体活化。结果显示SLE患者单核细胞炎性小体表达和ATP诱导的活化增强,IFNα长期暴露以IRF-1依赖方式促进caspase 1上调,敲低或抑制IRF-1可显著降低SLE单核细胞炎性小体高活性。
要点
- SLE患者单核细胞炎性小体表达和ATP诱导活化增强。
- IFNα长期暴露以IRF-1依赖方式促进炎性小体活化。
- 抑制IRF-1可降低SLE患者单核细胞炎性小体高活性。
核心结论
- SLE患者中长期的I型干扰素暴露以IRF-1依赖方式使单核细胞易于发生强烈的炎性小体活化。
- 抑制IRF-1可能成为治疗SLE相关炎症和器官损伤的新靶点。
研究设计与样本
- SLE患者符合≥4项美国风湿病学会标准,从密歇根大学狼疮队列招募。
- 通过阴性选择从SLE患者或健康对照分离原代单核细胞,在有无IFNα条件下用炎性小体激活剂处理,ELISA检测IL-1β分泌。
- 用实时聚合酶链反应和Western blotting评估IFN及炎性小体相关分子表达。
- 通过小干扰RNA转染和化学抑制剂特异性下调IRF-1表达。
主要发现
- 与对照单核细胞相比,SLE患者单核细胞在ATP刺激下炎性小体表达增加且活化增强。
- SLE患者单核细胞中炎性小体与IFN调控基因的表达显著相关,而对照单核细胞中无此相关性。
- 长期暴露于IFNα后炎性小体活性增加。
- 通过siRNA降低IRF-1表达可阻断IFNα处理后caspase 1的上调。
- 敲低或抑制IRF-1后,SLE患者单核细胞的炎性小体高活性显著降低。
临床怎么用
- IRF-1抑制可能作为治疗SLE相关炎症和器官损伤的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed. The aim of this study was to examine type I IFNs as regulators of the inflammasome. METHODS: SLE patients fulfilled ≥4 American College of Rheumatology criteria and were recruited from the University of Michigan Lupus Cohort. Primary monocytes were isolated from SLE patients or healthy controls by negative selection, treated with inflammasome activators in the presence or absence of IFNα, and IL-1β secretion was measured by enzyme-linked immunosorbent assay. Expression levels of IFN and inflammasome-related molecules were assessed by real-time polymerase chain reaction and Western blotting. IFN regulatory factor 1 (IRF-1) expression was specifically down-regulated by small interfering RNA (siRNA) transfection and a chemical inhibitor. RESULTS: Monocytes from patients with SLE exhibited increased expression and enhanced activation of the inflammasome by ATP when compared with control monocytes. Expression of inflammasome and IFN-regulated genes was significantly correlated in monocytes from SLE patients but not in control monocytes. Inflammasome activity was increased after prolonged exposure to IFNα. Reduction of IRF-1 expression via siRNA blocked caspase 1 up-regulation after treatment with IFNα. Importantly, hyperactivity of the inflammasome in the monocytes of SLE patients was significantly reduced after knockdown or inhibition of IRF-1. CONCLUSION: Prolonged type I IFN exposure, as seen in SLE patients, primes monocytes for robust inflammasome activation in an IRF-1-dependent manner. IRF-1 inhibition may serve as a novel target for treatment of SLE-associated inflammation and organ damage.
引用
- Liu J, Berthier CC, Kahlenberg JM, et al. Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1. Arthritis Rheumatol. 2017. PMID: 28564495. doi:10.1002/art.40166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。